Patents Examined by Lianko G Garyu
  • Patent number: 11028127
    Abstract: The invention provides peptides that can reactivate p53 mutants efficiently and specifically, as well as methods that allow the identification, selection and isolation of such peptides, in a precise, cost and time effective manner. In particular, there are provided mutant p53 reactivating peptides that can restore the native wild type p53 folding, and hence the tumor suppressor activity, to the mutant p53 protein. Such peptides are useful for treating various conditions and diseases in which p53 is mutated.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 8, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Moshe Oren, Varda Rotter, Perry Tal
  • Patent number: 11013781
    Abstract: The invention relates to combinations of peptides derived from a portion of an amino sequence of a grass pollen allergen, e.g. the allergens Phl p 1, Phl p 2, Phl p 3, Phl p 4 and/or Phl p 5, or a peptide variant thereof. Such peptides comprise at least one T cell epitope mid a high number of patients in a worldwide population will have HLA Class II alleles with the potential to bind the peptides of the peptide combinations. The invention also relates to the use of such peptide combinations in relieving an immune response caused by grass pollen species.
    Type: Grant
    Filed: July 1, 2016
    Date of Patent: May 25, 2021
    Inventors: Claus Lundegaard, Shashank Gupta, Bjoern Peters, Susanne Sønderkær, Jens Brimnes, Peter Adler Würtzen, Helene Henmar, Thomas Christian Mygind, Lise Lund Mærkedahl, Alessandro Sette
  • Patent number: 11014971
    Abstract: Described herein are peptibodies that can contain a TertiapinQ peptide, formulations thereof, and uses thereof. In some embodiments, the peptibody can include a first monomer and a second monomer, wherein each monomer can include an Fc polypeptide, a first TertiapinQ peptide, wherein the N-terminus of the first TertiapinQ peptide can be linked to the C-terminus of the Fc polypeptide via a first linker, and wherein the first monomer and the second monomer can be attached via a disulfide bridge between the Fc polypeptide of the first monomer and the Fc polypeptide of the second monomer. The compositions and formulations thereof can be used to treat atrial fibrillation.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: May 25, 2021
    Assignee: University of South Florida
    Inventors: Sami Fouad Noujaim, Michael Teng
  • Patent number: 11014970
    Abstract: The present disclosure describes analog conotoxin peptides of the ?-conotoxin peptide RgIA. These analog conotoxin peptides block the ?9?10 subtype of the nicotinic acetylcholine receptor (nAChR) and can be used for treating pain and inflammation including inflammatory pain, cancer related pain, and neuropathic pain. The RgIA analogs described in the present invention include a variety of sequence modifications and chemical modifications that are introduced to improve the drug-like characteristics of RgIA analogs and thereby increase their therapeutic value.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: May 25, 2021
    Assignee: Kineta Chronic Pain, LLC
    Inventor: Jeffrey Jerard Posakony
  • Patent number: 11008365
    Abstract: The present invention relates to a novel polypeptide having affinity for proteins partially including a CH1-CL domain forming a non-native three-dimensional structure and capable of being suitably used for detecting, immobilizing, or removing these proteins and relates to use of the polypeptide. Specifically, disclosed are a polypeptide consisting of an amino acid sequence represented by any one of the following formulas 1 to 3: (1) P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 1), (2) Y-D-P-E-T-G-T-W-P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 4), and (3) P-N-S-G-G-G-G-S-Y-D-P-E-T-G-T-W-P-Q-x-I-x-L-x-[IL]-[NT]-[YW] (SEQ ID NO: 7) (wherein x represents an amino acid residue; and brackets represent any one of the amino acid residues within the brackets), and a method of using the polypeptide to detect, purify, or remove a protein partially including a CH1-CL domain forming a non-native three-dimensional structure.
    Type: Grant
    Filed: August 31, 2017
    Date of Patent: May 18, 2021
    Inventors: Hideki Watanabe, Shinya Honda
  • Patent number: 11000057
    Abstract: Methods for lowering hypertension, elevated total cholesterol, elevated glucose and insulin, elevated IGF-1, elevated triglyceride levels, and/or elevated CRP levels, and elevated liver fat without negatively affecting or lowering the levels of these markers/factors in subjects with already low levels of these markers are provided. A method for elevating stem cells and regeneration and anti-inflammatory agents is also provided. Finally, a method for treating metabolic syndrome is also provided. A hypocaloric or calorie free diet or a fasting mimicking diet is administered for a first time period to the subject to reduce blood pressure or the levels of the above markers/risk factors for aging and age-related diseases.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 11, 2021
    Assignee: University of Southern California
    Inventors: Valter D. Longo, Sebastian Brandhorst, Min Wei
  • Patent number: 10994018
    Abstract: The present invention relates to a novel long-acting palmitic acid-conjugated gonadotrophin-releasing hormone (GnRH) derivative and a pharmaceutical composition containing the same. A GnRH derivative of the present invention is expected to greatly contribute, through excellent bioavailability and increased half-life in blood, to the reduction in drug dosing frequency and dosage and the like in the treatment of sex hormone-dependent diseases. Particularly, the GnRH derivative can overcome the disadvantages of existing GnRH sustained-release preparations, which have the side effects of residual feeling and pain at the injection site.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: May 4, 2021
    Assignee: NOVEL PHARMA INC.
    Inventor: Dong Kyu Jin
  • Patent number: 10973891
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 13, 2021
    Assignees: CSL Behring GmbH, Universitaet Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Patent number: 10973874
    Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: April 13, 2021
    Assignee: Hexima Limited
    Inventors: Nicole Louise van der Weerden, Marilyn Anne Anderson
  • Patent number: 10975124
    Abstract: The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: April 13, 2021
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: David Charles Kem, Xichun Yu, Hongliang Li, LaTasha B. Craig
  • Patent number: 10967038
    Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 6, 2021
    Assignee: Xigen Inflammation Ltd.
    Inventors: Jean-Marc Combette, Catherine Deloche, Claire Abadie
  • Patent number: 10954269
    Abstract: The present invention relates to tripeptide compounds according to the general formula (1) and their use as a medicament, in particular as anti-inflammatory agents.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: March 23, 2021
    Assignee: Dr. August Wolff GmbH & Co. KG Arzneimittel
    Inventors: Michael Soeberdt, Ulrich Knie, Christoph Abels
  • Patent number: 10953379
    Abstract: Methods and compositions are disclosed relating to the localization of nucleic acids to arrays such as silane-free arrays, and of sequencing the nucleic acids localized thereby.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: March 23, 2021
    Assignee: Illumina Cambridge Limited
    Inventors: Mark Edward Brennan Smith, Andrea Sabot, Isabelle Marie Julia Rasolonjatovo, Jean-Ernest Sohna Sohna, Adrian Martin Horgan, Harold Philip Swerdlow
  • Patent number: 10947271
    Abstract: The invention concerns agents with antibacterial activity, their production and use in the treatment of bacterial infections in animals, including man. The agents are derivatives of vancomycin-type antibiotics, of structure X—W-L-V, wherein X is hydrogen, acetyl or a lipophilic membrane-insertive element, W is a basic peptide or basic amino acid; L is a linking group and V is a glycopeptide moiety which inhibits peptidoglycan biosynthesis in bacteria.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: March 16, 2021
    Inventors: Matthew Cooper, Mark Blaskovich
  • Patent number: 10940170
    Abstract: Compositions and methods for treating or reducing the severity or likelihood of occurrence of a parasitic worm or helminth infection in a subject are described. The methods include administering to the subject a therapeutically effective amount of a recombinant bacterium expressing a crystal protein such as a Bacillus thuringiensis crystal protein (Cry). The crystal proteins may be full length, truncated, variant, or sub-variant Cry proteins. Examples of crystal proteins include Cry5B, Cry21, Cry14A, Cry6A, and Cry13A. The recombinant bacterium may be, for example, a Bacillus subtilis or other Gram-positive bacterium, for instance, a lactic acid fermenting bacterium such as Lactococcus or Lactobacillus. Related compositions and recombinant microorganisms are also described.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: March 9, 2021
    Inventors: Raffi Van Aroian, Yan Hu
  • Patent number: 10919948
    Abstract: The present disclosure provides recombinant polypeptides, homodimeric and heterodimeric proteins comprising the recombinant polypeptides, nucleic acid molecules encoding the recombinant polypeptides, and vectors and host cells comprising the nucleic acid molecules. The present disclosure also provides compositions comprising the recombinant polypeptides and methods of making and using the recombinant polypeptides.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: February 16, 2021
    Assignees: BioGend Therapeutics Co., Ltd., Osteopharma Inc.
    Inventors: Da-Wei Sun, Pei-Wen Hsu, Chien-Pei Chen
  • Patent number: 10912843
    Abstract: A method for treating a disease caused by protein retention in the endoplasmic reticulum (ER) with a sarcoplasmic/endoplasmic reticulum calcium ATPase pump inhibitor encapsulated in a polymer nanoparticle. The polymer nanoparticle is surface-modified such that it is targeted to the ER. The inhibitor reduces protein retention in the ER and the encapsulation lowers side effects of the inhibitor, e.g., cytotoxicity, as compared to administering the inhibitor without encapsulation. Also disclosed is a pharmaceutical composition that can be used for carrying out the method. Further provided is a transgenic mouse carrying in its genome a heterologous nucleic acid that encodes an H338Y mutant gp91phox protein. The transgenic mouse can serve as a model for human chronic granulomatous disease.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: February 9, 2021
    Assignee: National Cheng Kung University
    Inventors: Chi-Chang Shieh, Chia-Liang Yen, Dar-Bin Shieh, Si-Tse Jiang
  • Patent number: 10899799
    Abstract: The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B)n (I) wherein M, T, B and n ore as defined in claim 1.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: January 26, 2021
    Inventors: Sylvie Bay, Claude Leclerc, Richard Lo-Man
  • Patent number: 10899791
    Abstract: The present invention provides a method for synthesizing etelcalcetide or salts thereof, comprising the steps of: (a) synthesizing the D-amino acids in the formula (I) sequentially by Fmoc solid-phase synthesis, using a solid support as a starting material in solid phase peptide synthesis and sequentially synthesizing a D-form amino acid of formula (I) by Fmoc chemistry; deprotecting Fmoc group and acetylating the amino group to obtain a sequence A comprising protecting groups (PG) in the side chain of D-Cys and D-Arg; (b) removing the protecting group in the side-chain of D-Cys of the sequence A to form a sequence B; (c) disulfide formation at D-Cys of the sequence B by (PG)-L-Cys-OH to obtain a sequence C; (d) using a cleavage solution to remove the protecting groups of the sequence C to give etelcalcetide as formula (I). The present invention can shorten the steps and time for preparing Etelcalcetide.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 26, 2021
    Inventors: Kwang-Chung Lee, Kuang-Chan Hsieh, Hui-Wen Cheng, Chia-Sui Kao, Ya-Ling Huang, Wei-Ssu Wang
  • Patent number: 10849978
    Abstract: The present invention is intended to provide a nose drop having high absorption of peptide hormone oxytocin or an acid addition salt thereof, or a derivative thereof through nasal mucosa and little safety concern. The present invention is a pharmaceutical composition for administration to nasal mucosa containing oxytocin or an acid addition salt thereof, or a derivative thereof and a carboxyvinyl polymer, characterized by having an osmotic pressure ratio less than 1.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 1, 2020
    Assignee: Teijin Pharma Limited
    Inventors: Susumu Maruo, Atsuhiro Nagano, Yuko Nonaka, Ryo Furukawa